Stock Scorecard



Stock Summary for Astrazeneca plc (AZN) - $79.90 as of 8/29/2025 8:17:22 PM EST

Total Score

12 out of 30

Safety Score

68 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for AZN

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for AZN

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for AZN

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for AZN

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for AZN (68 out of 100)

Stock Price Rating (Max of 10) 9
Historical Stock Price Rating (Max of 10) 9
Stock Price Trend (Max of 10) 9
Book Value (Max of 10) 7
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 4
Dividend Yield Percentage (Max of 10) 4
Operating Margin (Max of 10) 5
Trading Volume (Max of 10) 10
Price to Earnings (Max of 10) 6
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for AZN

Controlled Release Drug Delivery Market Size FDA Approved Drugs Clinical Trials Companies Report 2030 8/29/2025 6:40:00 AM
UPDATE - Questex's Fierce Pharma Week Announces Star-Studded Lineup with Jamie-Lynn Sigler, James Van Der Beek, Selma Blair, Kelly Killoren Bensimon and John Duffield to Provide Powerful Stories of Resilience and Healing 8/28/2025 5:30:00 PM
MRK, Daiichi Begin Phase III Breast Cancer Study With ADC Candidate 8/28/2025 3:13:00 PM
Will Weak Gardasil Sales Continue to Be a Drag on MRK's Top Line? 8/28/2025 1:21:00 PM
IonQ or Rigetti: Who Wins From Microsoft's Cloud Quantum Push? 8/26/2025 7:00:00 PM
Regeneron Advances In Rare Disease Race With Positive Autoimmune Muscle Disorder Trial Data - Regeneron Pharmaceuticals ( NASDAQ:REGN ) 8/26/2025 4:33:00 PM
Voyager to Present at Upcoming Investor Conferences 8/26/2025 11:00:00 AM
Voyager to Present at Upcoming Investor Conferences - Voyager Therapeutics ( NASDAQ:VYGR ) 8/26/2025 11:00:00 AM
Tempus AI or Butterfly: Which AI Health Tech Stock is a Buy Now? 8/25/2025 7:00:00 PM
What's Going On With BeOne Medicines Stock Monday? - Royalty Pharma ( NASDAQ:RPRX ) , BeOne Medicines ( NASDAQ:ONC ) , Amgen ( NASDAQ:AMGN ) 8/25/2025 5:19:00 PM

Financial Details for AZN

Company Overview

Ticker AZN
Company Name Astrazeneca plc
Country USA
Description AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 6/30/2025
Next Earnings Date 11/6/2025

Stock Price History

Last Day Price 79.90
Price 4 Years Ago 53.38
Last Day Price Updated 8/29/2025 8:17:22 PM EST
Last Day Volume 2,820,727
Average Daily Volume 4,976,896
52-Week High 85.46
52-Week Low 60.83
Last Price to 52 Week Low 31.35%

Valuation Measures

Trailing PE 30.07
Industry PE 40.47
Sector PE 60.89
5-Year Average PE 19.50
Free Cash Flow Ratio 35.04
Industry Free Cash Flow Ratio 15.46
Sector Free Cash Flow Ratio 30.76
Current Ratio Most Recent Quarter 0.86
Total Cash Per Share 2.28
Book Value Per Share Most Recent Quarter 28.85
Price to Book Ratio 5.55
Industry Price to Book Ratio 28.68
Sector Price to Book Ratio 26.74
Price to Sales Ratio Twelve Trailing Months 4.39
Industry Price to Sales Ratio Twelve Trailing Months 25.19
Sector Price to Sales Ratio Twelve Trailing Months 13.32
Analyst Buy Ratings 7
Analyst Strong Buy Ratings 2

Share Statistics

Total Shares Outstanding 3,100,480,000
Market Capitalization 247,728,352,000
Institutional Ownership 16.73%

Dividends

Ex-Dividend Date 8/8/2025
Previous Dividend Amount 1.0500
Current Dividend Amount 0.5150
Total Years Dividend Increasing 0
Trailing Annual Dividend Rate 1.57
Trailing Annual Dividend Yield 1.94%
Forward Annual Dividend Rate 1.03
Forward Annual Dividend Yield 1.28%
5-Year Dividend Payments Count 10
3-Year Average Dividend Yield 2.28%
5-Year Average Dividend Yield 2.37%
1-Year Dividend Growth Rate Percentage 5.39%
3-Year Dividend Growth Rate Percentage 3.89%
5-Year Dividend Growth Rate Percentage 2.82%
All-Time Dividend Growth Rate Percentage 5.87%
Dividend Payout Ratio 59.06%

Income Statement

Quarterly Earnings Growth YOY 27.60%
Annual Earnings Growth 18.14%
Reported EPS 12 Trailing Months 2.66
Reported EPS Past Year 3.10
Reported EPS Prior Year 3.52
Net Income Twelve Trailing Months 8,295,000,000
Net Income Past Year 7,035,000,000
Net Income Prior Year 5,955,000,000
Quarterly Revenue Growth YOY 11.70%
5-Year Revenue Growth 17.27%
Operating Margin Twelve Trailing Months 24.10%

Balance Sheet

Total Cash Most Recent Quarter 7,058,000,000
Total Cash Past Year 5,488,000,000
Total Cash Prior Year 5,840,000,000
Net Cash Position Most Recent Quarter -17,656,000,000
Net Cash Position Past Year -21,018,000,000
Long Term Debt Past Year 26,506,000,000
Long Term Debt Prior Year 22,365,000,000
Total Debt Most Recent Quarter 24,714,000,000
Equity to Debt Ratio Past Year 0.61
Equity to Debt Ratio Most Recent Quarter 0.64
Total Stockholder Equity Past Year 40,786,000,000
Total Stockholder Equity Prior Year 39,143,000,000
Total Stockholder Equity Most Recent Quarter 44,719,000,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months 8,724,000,000
Free Cash Flow Per Share Twelve Trailing Months 2.81
Free Cash Flow Past Year 7,275,000,000
Free Cash Flow Prior Year 6,567,000,000

Options

Put/Call Ratio 0.32
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD 2.27
MACD Signal 2.15
20-Day Bollinger Lower Band 63.96
20-Day Bollinger Middle Band 71.91
20-Day Bollinger Upper Band 79.86
Beta 0.15
RSI 66.84
50-Day SMA 70.66
150-Day SMA 68.25
200-Day SMA 65.51

System

Modified 8/29/2025 6:17:49 PM EST